Preston Mason (United States of America)

Brigham & Women’s Hospital, Harvard Medical School Medicine
Dr. R. Preston Mason is a faculty member of the Cardiovascular Division at Brigham and Women’s Hospital and Harvard Medical School in Boston, Massachusetts, USA. Dr Mason is also President and Founder of Elucida Research, a biotechnology research. He has received many awards for his research in cardiovascular pharmacology and teaching over the past 30 years, including an honorary doctorate in science. He received a full scholarship for graduate and medical programs (MD/PhD) at the University of Connecticut School of Medicine. Prior to coming to Boston, he was on the faculties of the University of Connecticut School of Medicine and the Medical College of Pennsylvania (now Drexel University) where he was nominated for full professor. Dr. Mason has served on a number of grant review committees for the National Institute of Health and has been a reviewer for a number of prestigious journals. He has authored or co-authored more than 250 scientific publications, has multiple patents and receives frequent requests to speak at national and international conferences.

Author Of 3 Presentations

Live Q&A (ID 1370)

Are all omegas 3 made equal or Omega 3s – All for one and one for all? (ID 1369)

Session Type
CME Session
Session Time
18:00 - 19:15
Date
Sun, 30.05.2021
Room
Hall A (Live Q&A)
Lecture Time
18:33 - 18:48

O036 - Differential Effects of Omega-3 Fatty Acids on Lipopolysaccharide (LPS)-induced Macrophage Activation in Combination with COX inhibition (ID 138)

Session Type
Lipoproteins and Metabolism
Session Time
12:30 - 14:00
Date
Tue, 01.06.2021
Room
Hall B (Live Q&A)
Lecture Time
13:00 - 13:08

Abstract

Background and Aims

Macrophages contribute to chronic diseases by promoting inflammation. Macrophage activation results in increased inducible nitric oxide synthase (iNOS) expression which can be modulated by cyclooxygenase (COX) activity. As both a substrate and potential inhibitor of COX activity, the omega-3 fatty acid EPA may modulate iNOS activity. We investigated the effect of EPA and DHA on iNOS activity in LPS-activated macrophages.

Methods

Murine J774 macrophages were pretreated with vehicle, EPA or DHA over a range of concentrations (1.9µM-50µM) during a challenge with lipopolysaccharide (LPS) at 1.0 µg/ml in DMEM supplemented with 1% FCS. After 24 hr, iNOS activity was assessed by nitrite production using the Griess assay. As a positive control, nitrite measurements with EPA and DHA were compared in combination with the COX inhibitor diclofenac at 100 µM.

Results

Macrophage treatment with LPS increased nitrite levels. EPA treatment reduced LPS-induced nitrite production in a concentration-dependent manner with statistically significant reductions (Figure 1). The inhibitory effects of EPA on iNOS activity were significantly (p<0.0001; two-way ANOVA with Sidak’s multiple comparisons test, n=9) enhanced at all concentrations in the presence of diclofenac. By contrast, DHA did not significantly reduce LPS induced iNOS activity either in the absence or presence of diclofenac.epa inhibits lps-induced nitrite release that is enhanced with diclofenac.jpg

Conclusions

Our observations that EPA but not DHA reduced macrophage iNOS activity may contribute to our understanding of the reduced cardiovascular events as reported in the REDUCE-IT trial with an EPA only formulation. The ability of EPA to modulate macrophage activity has therapeutic implications for patients with cardiovascular risk.

Hide

Presenter of 2 Presentations

Live Q&A (ID 1370)

Are all omegas 3 made equal or Omega 3s – All for one and one for all? (ID 1369)

Session Type
CME Session
Session Time
18:00 - 19:15
Date
Sun, 30.05.2021
Room
Hall A (Live Q&A)
Lecture Time
18:33 - 18:48